van Veen E-B, Riegman P H J, Dinjens W N M, Lam K H, Oomen M H A, Spatz A, Mager R, Ratcliffe C, Knox K, Kerr D, van Damme B, van de Vijver M, van Boven H, Morente M M, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero J A, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, Oosterhuis J W
Medlaw Consult, P.O. Box 11500, 2502 AM Den Haag, The Netherlands.
Eur J Cancer. 2006 Nov;42(17):2914-23. doi: 10.1016/j.ejca.2006.04.028. Epub 2006 Oct 6.
The regulatory regimes for research with residual tissue and accompanying data differ widely between countries in the European Union (EU): from specific consent to opt-out or even no consent at all. This could greatly hamper research where the exchange of tissue and accompanying data has become the gold standard, like in TubaFrost. Instead of adhering to international guidelines, which have a democratic deficit, or an attempt for a new set of possible harmonising rules, TubaFrost chose to create a coordinating rule: if tissue may legitimately be used for a certain kind of research in the country where it was taken and under whose jurisdiction the patient falls, it may also be used for such research in the country where it is sent to in the context of a scientific program even if in that other country other regulations would apply for research with residual tissue taken from patients under their jurisdiction. This coordinating rule has a sound basis in EU law in general and will solve the problems related to diverging national regulatory regimes in the case of cross national research with residual tissue.
从要求特定同意到选择退出甚至完全无需同意。这可能会极大地阻碍研究工作,因为组织及相关数据的交换已成为黄金标准,比如在TubaFrost项目中。TubaFrost没有遵循存在民主缺陷的国际准则,也没有尝试制定一套新的可能的协调规则,而是选择创建一条协调规则:如果组织在其采集地所在国家以及患者受其管辖的国家可以合法地用于某种研究,那么在科学项目背景下,即使在接收组织的另一国家,对于在其管辖下的患者的剩余组织研究适用其他法规,该组织也可用于此类研究。这条协调规则总体上在欧盟法律中有坚实基础,并且将解决跨国利用剩余组织开展研究时各国监管制度不同所带来的问题。